Abstract: Pediatric tumors harbor very low numbers of somatic mutations and therefore offer few targets to improve therapeutic management with targeted drugs. In particular, outcomes remain dismal for patients with metastatic alveolar rhabdomyosarcoma (aRMS), where the chimeric transcription factor PAX3/7-FOXO1 has been implicated but problematic to target. In this report, we addressed this challenge by developing a two-armed screen for druggable upstream regulatory kinases in the PAX3/7-FOXO1 pathway. Screening libraries of kinome siRNA and small molecules, we defined PLK1 as an upstream-acting regulator. Mechanistically, PLK1 interacted with and phosphorylated PAX3-FOXO1 at the novel site S503 leading to protein stabilization. Notably, PLK1 inhibition led to elevated ubiquitination and rapid proteasomal degradation of the PAX3-FOXO1 chimeric oncoprotein. On this basis, we embarked on a preclinical validation of PLK1 as target in a xenograft mouse model of aRMS, where the PLK1 inhibitor BI 2536 reduced PAX3-FOXO1-mediated gene expression and elicited tumor regression. Clinically, analysis of human aRMS tumor biopsies documented high PLK1 expression to offer prognostic significance for both event-free and overall survival. Taken together, these preclinical studies validate the PLK1 -PAX3-FOXO1 axis as a rational target to treat alveolar rhabdomyosarcoma. Taken together, these preclinical studies validate the PLK1 -PAX3-FOXO1 axis as a rational target to treat alveolar rhabdomyosarcoma.
Introduction
Rhabdomyosarcoma is the most common pediatric soft tissue sarcoma and can be divided into two main subgroups with different outcomes reflecting distinct genetic backgrounds. Alveolar rhabdomyosarcoma (aRMS) is more aggressive than embryonal rhabdomyosarcoma (eRMS) and often displays resistance to conventional chemo-and radiotherapy resulting in a 5-year survival rate of only 30% (1) . Until now, there are no alternative therapeutic strategies to these conventional treatments. Searching for appropriate molecular targets, large proteomic screening and sequencing approaches have been undertaken showing that pediatric tumors harbor far fewer somatic mutations than adult tumors (2) . In contrast to eRMS, analyzing genetic landscapes of alveolar rhabdomyosarcoma even further minimized the number of potential targets and excluded enrichment of any mutated oncogenic canonical pathway in the majority of patients (3, 4) . These findings indicate that aRMS is driven by very few individual oncogenes and consequently reinforce the focus on the role of the tumor specific chimeric transcription factor PAX3/7-FOXO1.
The fusion protein is expressed in about 80% of aRMS tumors suggesting a dominant role as oncogenic driver (4, 5) . Its transforming capacity (6, 7) is underlined by the ability to affect multiple oncogenic downstream pathways (8) (9) (10) (11) (12) (13) . Furthermore, aRMS is addicted to expression of the fusion protein as its continuous activity is essential for maintaining tumor cell survival (14, 15) . Finally, its presence has also important prognostic significance (16, 17) . PAX3-FOXO1 is, in conclusion, a highly relevant potential target and offers the opportunity for development of novel directed therapies.
However, directly antagonizing transcription factors remains a pharmaceutical challenge and alternative indirect strategies interfering with the regulatory network of the fusion protein need to be developed.
PAX3-FOXO1 is characterized by high expression, exclusive nuclear subcellular localization, enhanced protein stability, and increased transcriptional activity compared to wild type PAX3 or FOXO1 (18) (19) (20) (21) (22) . Currently, we aim to mechanistically understand these different levels of regulation required for the oncogenic function. We, as well as others, were able to demonstrate that the transcriptional activity of PAX3-FOXO1 depends on its phosphorylation state providing novel therapeutic opportunities (23) (24) (25) .
Polo-like kinase 1 (PLK1) is known as key regulator of mitosis with critical roles in mitotic entry, centrosome maturation, cohesin release, bipolar spindle formation, mitotic exit, and cytokinesis. Overexpression of PLK1 is linked to poor prognosis in a variety of different cancers (26, 27) . In contrast to healthy cells, it localizes to the nucleus already before G2-M in cancer cells and can be detected during the entire interphase (28) . Therefore, cancer-cell specific functions in G1-S transition and DNA replication are suggested beyond its role in regulation of mitosis. Interestingly, PLK1 is associated with PI3K and MAPK pathways, both of which are thought to play important roles in aRMS (29, 30) . Hence, PLK1 overexpression might not just be a consequence of enhanced proliferation, but it is likely that PLK1 actively contributes to early carcinogenesis. However, a specific role for PLK1 in aRMS has not yet been described.
Here, we utilized a two-armed screening strategy to identify PLK1 as upstream regulator of PAX3-FOXO1, whereby PLK1 phosphorylated and subsequently stabilized the fusion protein. Since we observed objective regression of xenograft tumors upon PLK1 inhibition and found that PLK1 expression in patient biopsies has significant prognostic value, we propose the PLK1 -PAX3-FOXO1 axis to be a very promising novel target for aRMS therapy.
Material and Methods

Cell lines
The 
Plasmids and transfection methods
Plasmids and transfection methods are described in Supplementary Material and Methods.
siRNA kinome library screens and data analysis
A kinome siRNA library targeting 719 kinases was used (Ambion Silencer ® V3 Kinase siRNA Library, Life Technologies, Zug, Switzerland) together with a sub-library targeting 47 kinases (Ambion Silencer ® Select Costum siRNA Library, Life Technologies) with 3 unique siRNA sequences per gene. Ambion non-targeting siRNA served as negative control, whereas PAX3-FOXO1 break-point specific siRNA (33) , luciferase specific siRNA (pGL4, Custom Select) and KIF11 siRNA (AM4639; all Ambion, Life Technologies) were used as positive controls. Reverse transfection was carried out with 1x10 4 cells per 96-well at a final concentration of 50 nM using N-TER nanoparticle transfection reagent (Sigma-Aldrich). Luciferase activity was determined by the Luciferase Assay System E1501 (Promega, Dübendorf, Switzerland) 48h post transfection and values normalized to viable cell numbers determined by WST-1 assay (Roche Diagnostics, Rotkreuz, Switzerland). Measurements were normalized using the per-plate median normalization method (excluding controls). Triplicate median-normalized luciferase values were averaged for each kinase before calculating the ratio to the averaged WST-1 absorbance (normalized luciferase activity). Cell viability of Rh4 and RMS13 cells was measured 72h post transfection using WST-1. Both screens were done in triplicates and non-targeting, PAX3-FOXO1, pGL4 and KIF11 siRNAs were included in duplicates on each plate.
Small-molecule compounds screen and dose response studies
A small-molecule compound library (Supplementary Tab. S2) covering 161 different inhibitors was used to treat 5x10 3 Rh4-AP2-LF cells per 96-well 24h after plating at a final concentration of 500 nM for 24h. Luciferase activity/cell viability ratio was determined as described above. For dose response curves, this ratio was plotted against the logarithm of drug concentrations and IC50 values were calculated by nonlinear regression curve fitting using GraphPad Prism software (GraphPad Software Inc., San Diego, CA, USA).
PLK1 silencing and small-molecule inhibition
Knockdowns of PLK1 and PLK4 were achieved by reverse transfection of 1.9-3. 
qRT-PCR
Total RNA was extracted using the Qiagen RNeasy Kit (Qiagen, Basel, Switzerland) and reverse-transcribed using oligo (dT) primers and Omniscript reverse transcriptase Cycle threshold (CT) values were normalized to GAPDH (Hs02758991_g1). Relative expression levels were calculated using the ΔΔCT method based on experiments performed in triplicates. Geometric mean values and the 95% confidence interval were calculated based on four to six biological replicates.
Immunoblotting
Total cell extracts were separated using 4-12% Bis-Tris SDS-PAGE gels (Life Technologies) and transferred to nitrocellulose membranes (PROTAN, Schleicher & Schuell, Kassel, Germany). After blocking with 5% milk powder in TBS/0.1% Tween, membranes were incubated with primary antibodies overnight at 4°C. After washing in TBS/0.1% Tween, membranes were incubated with IgG HRP-linked antibody for one hour at room temperature. Proteins were detected using ECL detection reagent (Fisher Scientific, Wohlen, Switzerland) after washing in TBS/0.1% Tween.
Antibodies
Antibodies are described in Supplementary Material and Methods.
Co-immunoprecipitation
Cells from one confluent 10 cm dish were lysed in 1 ml lysis buffer and incubated for 10 min at 4°C with Dynabeads ® Protein G (Novex by Life Technologies) coupled to indicated antibodies. Beads were washed three times with lysis buffer, proteins eluted in 1x NuPAGE LDS sample buffer (Life Technologies) at 70°C and analyzed by Western blotting. 
Stability assay
Purification of FLAG-PAX3-FOXO1
Rh4, RMS13 or HEK293T cells were transfected with pCMV-NFLAG-PAX3-FOXO1 in 15 cm plates, lysed 40h post transfection and FLAG-PAX3-FOXO1 was immunoprecipitated using 75 μl Dynabeads ® per plate coupled to 8 μg monoclonal ANTI-FLAG ® M2 antibody.
After washing, bead-bound FLAG-PAX3-FOXO1 was either used for in vitro kinase assays or the protein was eluted by 1x NuPage LDS buffer and directly subjected to mass spectrometry.
In vitro kinase assay and mass spectrometry
Bead-bound protein was dephosphorylated using 300 units CIAP enzyme (alkaline phosphatase, calf intestinal HC, Promega, Dübendorf, Switzerland) for 90 min at 37°C (50 mM Tris HCl pH 7.5, 1 mM MgCl2, 0.1 mM ZnCl2). FLAG-PAX3-FOXO1 was phosphorylated after washing using 500 ng or 2.5 μg of recombinant PLK1 (Life Technologies) for 30 min at 30°C (250 mM HEPES pH 7.5, 50 mM MgCl2, 12.5 mM DTT, 0.05% Triton X-100, 200 μM ATP). 4x NuPage LDS buffer was added for elution and proteins were separated by gel electrophoresis. After staining with colloidal coomassie (Instant blue, Expedeon, Harston, UK), the band corresponding to FLAG-PAX3-FOXO1 was excised and prepared for mass spectrometry as described in Supplementary Material and Methods.
Ubiquitination studies
Rh4 cells were transfected with pCMV-FLAG-PAX3-FOXO1 plasmid and pCDNA3-HAUbiquitin at a ratio of 1:2 for 48h. Cells were treated with 200 nM PLK1 inhibitors for 21h prior to addition of 10 μM MG-132 (Calbiochem, Millipore, Zug, Switzerland) for 5h.
After lysis (2% SDS, 150 mM NaCl, 10 mM Tris/HCl, 2 mM Na3VO4, 50 mM NaF), samples were boiled for 10 min, sonicated, diluted with 9 volumes of dilution buffer (150 mM NaCl, 10 mM Tris/HCl, 2 mM EDTA, 1% TritonX) and incubated for 30 min at 4°C. IP was performed using Dynabeads ® coupled to ANTI-FLAG ® M2 antibody for 1h at 4°C. Beads were washed three times with lysis buffer, proteins eluted with 3x FLAG peptide (Sigma-Aldrich) and analyzed by Western blotting.
Xenograft studies 5x10 6 Rh4, Rh4luc or RMS13luc cells were engrafted subcutaneously in 6 weeks old NOD/Scid il2rg -/-mice (male and female, 20-25 g, Charles River, Sulzfeld, Germany).
Mice bearing established tumors with volumes of 65 -470 mm 3 were treated intravenously with either sterile 0.9% NaCl or BI 2536 at 40 mg/kg on two consecutive days weekly for three cycles. BI 2536 was formulated in hydrochloric acid (0.1 N) diluted with 0.9% NaCl (34) . Total tumor volumes were determined either by measuring two diameters (d1, d2) in right angles using a digital caliper (V= (4/3) π r³; r= (d1+d2)/4) or by in vivo imaging. D-luciferin (Caliper Life Sciences, Oftringen, Switzerland) was injected intraperitoneally (10 µl/g body weight), and tumors were monitored by the IVIS Lumina XR imaging system (Caliper Life Sciences). Control mice were euthanized when reaching a tumor volume of 1000 mm 3 .
Immunohistochemistry
Three-micron thick sections of formalin-fixed, paraffin-embedded tissue were mounted on glass slides (SuperFrost Plus; Menzel, Braunschweig, Germany), deparaffinized, rehydrated and stained with hematoxylin and eosin (H&E). Immunohistochemical stainings were performed using the Ventana Benchmark system (Ventana Medical Systems, Tucson, AZ) and Ventana UltraView DAB reagents.
Tissue arrays
Tissue arrays have been previously described (35, 36) . Immunohistochemistry was performed on Leica BondMax instruments using Refine HRP-Kits (Leica DS9800, Leica Microsystems Newcastle, Ltd.). Paraffin-slides were dewaxed, followed by pretreatment (Epitop Retrieval Buffer 2, 45 min, 100°C) and incubated with anti-PLK1 antibody (1:600). Tumors showing at least 1-5% of cells with a very high staining intensity were assigned to the high expression group. In contrast, tumors with low expression showed homogenous overall staining of reduced intensity. TMAs were analyzed double-blinded.
Results
Kinome-wide siRNA screen identifies PAX3-FOXO1 regulators
To identify kinases regulating the activity of the oncogenic transcription factor PAX3-FOXO1, we established a stable reporter cell line to monitor fusion protein activity (Fig.   1A ). Rh4 aRMS cells with a transcriptome very similar to tumor biopsies (13) were stably transfected with a PAX3-FOXO1-responsive luciferase reporter employing a wellcharacterized endogenous AP2β promoter fragment (10) to generate Rh4-AP2β-LF cells.
Depletion of PAX3-FOXO1 by siRNA (33) or silencing of luciferase itself resulted in a more than 70% decrease in luciferase activity ( Supplementary Fig. S1A ). Therefore, this reporter assay constitutes a valid tool for functional screening of PAX3-FOXO1 upstream regulators.
First, we performed a kinome-wide siRNA screen ( Figure 1A ). Rh4-AP2β-LF cells were transfected with three unique siRNA sequences targeting each of the 719 kinases ( Fig.   1B and Supplementary Fig. S1B ). PAX3-FOXO1, KIF11 (mitotic motor protein) and luciferase control siRNAs were included on each plate and the ratio of luciferase activity to cell viability from averaged triplicate values was determined for each siRNA. Only siRNAs that reduced this ratio by at least 1.5 SDs from the mean of the luciferase control were considered as potential candidates. Applying this criterion for at least two independent siRNAs, we identified 47 candidates that potentially contribute to the activity of PAX3-FOXO1 (Supplementary Tab. S1). Importantly, these kinases are all expressed in Rh4 cells and primary aRMS tumors, at least at the mRNA level (9, 13).
To narrow down the list of candidates, we applied a secondary viability screen using an siRNA library containing three additional targeting sequences per kinase (sequence panels A, B and C). We determined mean relative cell viability after individual silencing for 72 hours in Rh4 and RMS13 cells. Next to two positive controls (PAX3-FOXO1 and KIF11) included on each screening plate, we found that knockdown of PLK1 clearly had the strongest impact on cell viability in both cell lines (up to 61% reduction), whereas the per-plate means reached only 7% to 22% (Fig. 1C) . These results suggest that PLK1 expression might be important for aRMS cell survival.
Small-molecule inhibitor screen reveals PLK1 as potential PAX3-FOXO1 regulator
In parallel to the siRNA screen, we conducted a small-molecule, mainly kinase-directed drug screen, to further examine the regulation of PAX3-FOXO1 activity (Fig. 1A) . This approach is able to directly identify available pharmaceutical inhibitory compounds. We Fig. S2C ). To demonstrate the potential relevance of PLK1 in aRMS, we analyzed the expression of PLK1 protein across a panel of eight different aRMS cell lines by immunoblotting. All of the cell lines expressed the kinase with Rh4, Rh41 and RMS13 cells displaying the highest protein levels (Fig. 1F ).
In conclusion, we identified PLK1 as the most promising candidate kinase by both siRNA and small-molecule compound screen, which therefore represents a potential target for treatment of aRMS.
PLK1 inhibition reduces PAX3-FOXO1 activity
To confirm PLK1 as regulator of the fusion protein, we analyzed a panel of PAX3-FOXO1 target genes. We measured relative mRNA expression of the activated target genes AP2β, FGFR4, CDH3 and PIPOX (8, 9, 12, 13, (36) (37) (38) and the repressed differentiation marker MYL1 (39) by qRT-PCR after 48 hours of either PLK1 silencing (si1341 and siS449) or small-molecule inhibition (BI 2536 and BI 6727). In RMS13 cells, knockdown of PLK1 achieved 80% (si1341) and 82% (siS449) of silencing without affecting PAX3-FOXO1 mRNA expression. However, expression of all target genes was significantly modulated ( Fig. 2A) . In Rh4 cells, knockdown efficiencies by si1341 reached 86% with similar modulation of target gene expression, whereas silencing by siS449 reached 81% without significant effects on target genes (Fig. 2B) . Nevertheless, treatment with both inhibitors, BI 2536 and BI 6727, significantly affected target gene expression in both cell lines.
In summary, PLK1 inhibition, either by genetic or pharmacological means, significantly altered transcription of PAX3-FOXO1 downstream targets suggesting a specific link between the kinase and the fusion protein.
PLK1 binds to and phosphorylates PAX3-FOXO1
We assessed direct interaction of PLK1 and PAX3-FOXO1 by co-immunoprecipitation of the endogenous proteins in Rh4 cells. PAX3-FOXO1 was pulled down using either anti-PAX3 or anti-FOXO1 antibody. In both cases, PLK1 was co-immunoprecipitated with the fusion protein but not with the negative control as shown by Western blot analysis (Fig.   3A) . In a reciprocal approach, the kinase was pulled down by anti-PLK1 antibody and PAX3-FOXO1 was found to co-immunoprecipitate as well (Fig. 3B) . These findings indicate that PLK1 and PAX3-FOXO1 can directly interact in aRMS cells.
Furthermore, we interrogated this interaction under drug treatment conditions. Rh4 cells were transfected with FLAG-tagged PAX3-FOXO1 or FLAG-tagged GFP, which were then immunoprecipitated after DMSO or BI 2536 treatment for 16 hours using an anti-FLAG antibody. Again, we found PLK1 to interact with the fusion protein, but not with GFP (Fig. 3C) . Surprisingly, interaction even increased after treatment with BI 2536, which arrested cells in G2-M ( Supplementary Fig. S2D and (34, 40) ). This indicates that PLK1 might control PAX3-FOXO1 mainly at the transition to mitosis.
PLK1 substrates contain the consensus motifs [D/E/N]Xp[S/T] or p[S/T]F (41) and
several of these can also be found in PAX3-FOXO1 suggesting that it might be a direct target of PLK1. In silico analysis using GPS-Polo 1.0 (42) predicted S503 and S457 as potential phosphorylation sites with a high cut-off threshold (Fig. 3D) . To directly analyze whether one of these consensus sites is phosphorylated in the fusion protein, FLAG-tagged PAX3-FOXO1 was purified from aRMS cells. Using mass spectrometry, we identified the peptide TSSNASTISGR containing S503 as one out of eleven phosphopeptides (Supplementary Tab. S3). Furthermore, applying a phospho-specific antibody to exactly localize the phosphorylated residue, we detected phosphorylation at S503+S506 (corresponding to phospho-S322+S325 in FOXO1 against which the antibody is directed) directly demonstrating that the predicted site is phosphorylated in aRMS cells (Fig. 3E) .
To assess whether PLK1 can phosphorylate S503, we purified FLAG-PAX3-FOXO1 from HEK293T cells, dephosphorylated the protein by calf intestine alkaline phosphatase (CIAP) and subsequently performed in vitro kinase assays using recombinant PLK1.
Mass spectrometry confirmed that PLK1 phosphorylated the peptide TSSNASTISGR. In total, this peptide contains six serine or threonine sites, but the data indicated that only S503 or T504 could be considered as potential phosphorylation sites ( Supplementary Fig. S3 ). To distinguish these two possibilities, we used the phospho-specific antibody recognizing phospho-S503+S506. Western blot analysis indeed revealed specific phosphorylation at these positions indicating that S503 is the site being phosphorylated by PLK1 (Fig. 3F) .
These data suggest that PLK1 and PAX3-FOXO1 are direct interaction partners and that PLK1 can phosphorylate the fusion protein at S503.
PLK1 stabilizes PAX3-FOXO1 protein
To further explore the biological functions of this phosphorylation site, we transfected RD eRMS cells lacking endogenous PAX3-FOXO1 with plasmids expressing either PAX3-FOXO1 wild type or mutated PAX3-FOXO1-S503A. Cells were then treated with cycloheximide for 6 hours to assess protein turnover by immunoblotting and densitometric quantification. Interestingly, the mutant protein was significantly less stable than the wild type protein (protein amount reduced by 47%) (Fig. 4A and 4B) .
Next, the stability of endogenous PAX3-FOXO1 upon PLK1 depletion was examined in two aRMS cell lines. Treatment with 8 nM siRNA 1341 for 48 hours reduced PLK1 protein by 43% in RMS13 cells and 53% in Rh4 cells respectively and induced a slight degradation of PAX3-FOXO1 (23% and 11%, calculated from representative blots shown in Fig. 4C ). Upon silencing with the more efficient siRNA S449 (reduction of PLK1 by 94% (RMS13) and 83% (Rh4)), we observed degradation of the fusion protein by 48% and 41% compared to scrambled control treatment (Fig. 4D) . These results suggest that stability of PAX3-FOXO1 is modulated by phosphorylation at S503. Indeed, inhibition of PLK1 activity by BI 2536 (15 nM) and BI 6727 (20 nM) led to similar reduction of PAX3-FOXO1 protein levels (53% and 64% in RMS13, 44% and 49% in Rh4 cells) (Fig. 4E ). In addition, increased ubiquitination of PAX3-FOXO1 upon PLK1 inhibition confirmed its proteasomal degradation (Fig. 4F) , which moreover, could be rescued by adding low concentrations of the proteasomal inhibitor Bortezomib (43) in a dose dependent manner (Fig. 4G ).
In conclusion, these experiments imply that PLK1-mediated phosphorylation at S503 protects PAX3-FOXO1 from ubiquitination and consequent proteasomal degradation and thus maintains the transcriptional activity of the fusion protein. were treated intravenously with vehicle or BI 2536 at a dose of 40 mg/kg for three weeks on two consecutive days per week (34) . Every treatment group of three to five mice included two mice with large tumors of at least 300 mm 3 . Absolute tumor volumes measured by caliper in mice bearing Rh4 tumors revealed a complete tumor regression upon BI 2536 treatment in all mice, even when the starting volume was as high as 370 mm 3 (Fig. 5A) . Similarly, luciferase activity was reduced in both cell lines by close to 100% ( Fig. 5A and 5B). Tumors of additional mice were treated for two cycles only, isolated after a two-week recovery phase, paraffin-embedded, and immunohistochemically stained. Vehicle treated tumors showed highly cellular histology with strong expression of Myogenin and AP2β consistent with aRMS. In contrast, treated xenografts displayed a high degree of necrotic areas and fibrosis.
PLK1 inhibition causes tumor regression in xenografts
Importantly, expression of PAX3-FOXO1 target genes AP2β and P-Cadherin (CDH3) was significantly lower compared to untreated xenografts.
These data impressively illustrate that PLK1 activity plays a major role in aRMS tumor cell survival corroborating our in vitro results. Therefore, PLK1 inhibitors such as BI 2536 might represent very potent novel treatment options for aRMS.
PLK1 is overexpressed in human tumor biopsies and correlates with PAX3-FOXO1 activity and survival
To ensure that our findings are not restricted to aRMS cell lines, PLK1 expression was analyzed in patient tumor biopsies. We utilized PLK mRNA expression data of PAX3-FOXO1 positive aRMS tumors from two independent data sets (9, 13) and compared them to PLK expression in normal muscle tissue (44) . We found that mRNA levels of PLK1 and PLK4, but not PLK2 and PLK3, were significantly higher in tumor samples than in normal muscle biopsies ( Fig. 6A and Supplementary Fig. S4 ).
To validate PLK1 as a clinically relevant therapeutic target, we immunohistochemically stained a tissue microarray including tumor biopsies of 49 aRMS patients. Tumors were divided into high and low expressing subgroups as described in Material and Methods ( Fig. S5 ). These results support our previous findings and a mechanism whereby activity of PAX3-FOXO1 is modulated by PLK1.
Importantly, outcome as measured for event free (EFS) and overall survival (OS) by
Kaplan-Meier analysis was significantly worse for patients with high PLK1 expression (Fig. 6D) . Five-year survival rates for patients in the PLK1 high expression cohort were only 15.4% (EFS) and 20.2% (OS). Therefore, the hazard ratio for events was 2. In summary, our results imply that PLK1 is a highly attractive target for the treatment of aggressive aRMS, which warrants further investigations in clinical studies.
Discussion
This study describes a novel PLK1 -PAX3-FOXO1 oncogenic axis in aRMS. We show modulation of PAX3-FOXO1 activity by PLK1 based on direct protein-protein interaction To improve previous screenings for targets in aRMS, which concentrated mainly on cell viability (45), we focused on transcriptional activity of PAX3-FOXO1 by employing aRMS (Rh4) cells stably expressing an AP2β-promoter reporter construct. Using the ratio of reporter activity versus cell viability, we were able to exclude generally cytotoxic drugs.
Strikingly, a kinome-wide siRNA as well as a small-molecule library screen identified PLK1 as top hit. KEGG pathway analysis (string-db.org) showed that several additional candidates are associated with MAPK or phosphatidylinositol signaling, both of which have been previously reported in RMS (27) .
To confirm PLK1 as an upstream modulator of PAX3-FOXO1 activity, we assessed expression of known endogenous PAX3-FOXO1 target genes (AP2β, FGFR4, CDH3, PIPOX and MYL1) upon inhibition by two drugs as well as by two different siRNAs in two aRMS cell lines. We observed significant target gene modulation with the exception of one siRNA in Rh4 cells. It is likely that the lack of activity might be due to compensatory effects by other members of the PLK family since BI 2536 and BI 6727 are known to affect the activities of PLK2, PLK3 and potentially PLK4 (34, 46) . Indeed, next to PLK1 also PLK4 is overexpressed in aRMS biopsies compared to normal muscle and, although not identified in the primary screen, its depletion reduced target gene expression in Rh4 cells suggesting overlapping functions of PLK1 and PLK4
( Supplementary Fig. S6 ). Nevertheless, our findings support the conclusion that PLK1
regulates PAX3-FOXO1 activity.
To Program (51). This particular xenograft was derived from a patient that had failed prior therapies suggesting that PLK1 expression might be of prognostic relevance. Indeed, expression of PLK1 in 49 aRMS tumor biopsies significantly predicted poor prognosis for event free and overall survival. To our knowledge, PLK1 expression is therefore one of the first predictive markers next to EPHB4 that is able to stratify patients within the group of fusion-positive tumors (52).
Summarizing, our data suggest that PLK1 is a highly relevant clinical target in aRMS with several PLK1 inhibitors already in clinical development. Since it has been shown that mice can tolerate higher systemic exposure to PLK1 inhibitors than humans (51), it is likely that combination therapies need to be developed to overcome this obstacle.
Nevertheless, this study reveals an important new role for PLK1 in aRMS biology apart from its known function in cell cycle that might explain increased sensitivity. Hence, our results should be directly translatable to clinical studies. Columns, geometric mean of at least 4 independent experiments performed in triplicates; bars, 95% confidence interval; * significant according to 95% CI 
